Home » Cardiovascular » COMPASS Trial: Rivaroxaban plus aspirin in stable cardiovascular disease

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
compass trial visual abstract on rivaroxaban use with or without aspirin in CAD

Does adding rivaroxaban to aspirin therapy in patients with stable cardiovascular disease affect outcomes? This was the question answered by the large-sized multi-center COMPASS trial that evaluated the combination of rivaroxaban and aspirin and compared it with aspirin alone. The results showed moderate improvement in outcomes at the expense of increased bleeding risk.

Source: NEJM

COMPASS Trial: Rivaroxaban plus aspirin in stable cardiovascular disease